Tenet Healthcare's Ambulatory Growth Offsets Emerging Policy Headwinds

Impact · against what's priced in

Tenet Healthcare (THC) is a strong buy on the back of significant guidance raises and a $2B buyback expansion. The shift toward high-margin ambulatory growth is successfully offsetting systemic headwinds in the hospital segment.

THC+0.80

No priced-in read yet

In context

The combination of a 43.5% increase in non-GAAP EPS, raised FY2026 revenue guidance to $5.03B, and a $2B increase in share repurchases provides a material catalyst for valuation expansion.

Read from the article alone

• cash flow▲12%
• guidance▲10%
• earnings▲5%
• healthcare
• THC
• aca
• ambulatory care